London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agreed but its fluid what the bod considers attractive before the end of P1b vs LTH’s is another matter either way we are in the end game so GLA.
Annual Report 2024 objectives: License drug candidates to pharmaceutical company partners
Once the planned Phase 1b clinical trial of SDC-1801 is completed, expected by end of calendar year 2024, we believe we will have a comprehensive clinical data package that should be attractive to potential licence partners.
However, we will maintain our dialogues with potential partners and, should the opportunity for an attractive licence deal arise before the completion of this Phase 1b, we would give it serious consideration.
Is there a licence deal in the air ?
Oops ... @42.25p
Last few 'sells' @ 42.24p (3 no atm) are buys.
Wouldn't it be great now to see them hoover up any shares on the market and to announce who it is.. I really cant believe anyone is selling at these prices even RF - they should be buying more, now theyve helped push it down.
And shouldnt they do an RNS about that tweet/article in Business Weekly as its effecting the share price :-)
Damion - it will need to demonstrate efficacy first… at least to achieve the sort of deal we would like to see.
Brepocitinib is far more clinically developed.
https://priovanttx.com/pipeline.html
Sareum are not at this stage and any offer will reflect that
Krusty and I not saying they have - I used the word "if" - it's just an opinion on a bb that's all!
Agree some pi's may have decided to get out, but, I think you would agree they wouldn't have done so before any selling down by RF going back as far as last August.
Anyway, time for a walk, hopefully, today's momentum continues and sticks which is of more concern to me!
GLA
PCS I'm not saying they haven't sold any, just that we can't say for sure that they have. The sp has dropped alarmingly on very little volume, which suggests to me that PI's have been frightened out of their shares by some of the scare stories on this and other boards. The sp is rising significantly but still on very few trades, this has been one of the hallmarks of SAR over the years I have found. MM antics in the main.
If 1a data shows SDC-1801 can be administered at a higher dosage than (Brepocitinib 30–60mg) with the same or better safety profile IMO we won’t even make it to 1b before a license deal or a T/O happens…. RF Redundant means to an end /
Granted Krusty. but, lets just say the general conversation at the AGM, along with the Q & A answer that a register of sells is being kept would suggest they have imho!
If as you say they haven't sold a single share, the gap is closing this morning on the dilution - long may it continue!
GLA
''I think Parker was very naive with this funding and probably did not assume RF would sell down and trash our SP so as to get their free top-ups at such low ball prices''
To be honest, if Parker didn't see foresee this as the potential risk it was then IMO he has no right holding the position he currently does, whilst drawing the £90k odd salary he gets!!!! 😡🤬🤬😡
To be fair, we don't know that RF has sold a single share...
40p on the bid!
Hi Bobbler - I'm guessing OPUS couldn't finance us as it'd be a conflict of interest with SP involved in both companies.
As I said, perhaps RF not so clever in selling down - food for thought!!
GLA
40% up now...
Hopefully, finally, up we go...
GLA!
Finally, they are starting to tell the word what they have. I hope for lots more publicity soon. Good to see that it links to a rising SP... Bought some more this morning - an absolute bargain at these prices!!
We are pleased to have been featured in Business Weekly newspaper following our recent positive clinical update on our randomised and placebo-controlled Phase 1a clinical trial for our lead candidate #SDC-1801. These preliminary results indicate that SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events.
Read the full article here: https://lnkd.in/e2zBMdqw
KR
ZA
Not forgetting of course that RF can exercise warrants at £1.43p - meaning more money into the coffers if exercised.
RF selling down might not be their best option, now we have progressed in Phase1a as I've I mentioned previously gives an opportunity for alternative funding - the terms of the RF facility says it is terminated on repayment of such - do that and RF has "bridged" us to get where we are today and they are left with whatever shares they haven't sold.
As I said we do have "meat on the bones" now which hopefully will allow for a more beneficial funding arrangement akin to the Sareum business model.
GLA
I was surprised to read on the Advfn board
That Stephen Parker is part of OPUS Corporate Finance, which is correct. Considering what Opus do, (capital raising) RF seems a bizarre choice.
https://opuscf.com/people/dr-stephen-b-parker/
Their plan might be to get as many 'bonus' shares as possible and just sit on them until we get a license deal then benefit massively.
They have a motive behind this !!
They are finishing off their original 2M Shares quota so as to get a fairly hefty (> 1M IMHO) top-up at a ridiculously low price; Unfortunately I think Parker was very naive with this funding and probably did not assume RF would sell down and trash our SP so as to get their free top-ups at such low ball prices
And unfortunately it now means that any attempt to push the SP upwards is instantly taken advantage of by them
ARGHHHH
There are plenty that do carter. Anyway, things looking up a bit this morning are they not?